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Abstract
Background: The emergence of carbapenemase producing bacteria, especially New Delhi metallo-β-lactamase
(NDM-1) and its variants, worldwide, has raised amajor public health concern. NDM-1 hydrolyzes a wide range of
β-lactam antibiotics, including carbapenems, which are the last resort of antibiotics for the treatment of infections
caused by resistant strain of bacteria.
Main body: In this review, we have discussed blaNDM-1variants, its genetic analysis including type of specific
mutation, origin of country and spread among several type of bacterial species. Wide members of enterobacteriaceae,
most commonly Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and gram-negative non-fermenters
Pseudomonas spp. and Acinetobacter baumannii were found to carry these markers. Moreover, at least seventeen
variants of blaNDM-type gene differing into one or two residues of amino acids at distinct positions have been
reported so far among different species of bacteria from different countries. The genetic and structural studies of
these variants are important to understand the mechanism of antibiotic hydrolysis as well as to design new molecules
with inhibitory activity against antibiotics.
Conclusion: This review provides a comprehensive view of structural differences among NDM-1 variants, which are a
driving force behind their spread across the globe.
Keywords: Enterobacteriaceae, New Delhi-Metallo-Beta-Lactamases, Carbapenemases, Antibiotic resistance
Background
Although antibiotics were developed to fight infections,
the emergence of new resistant markers, especially New
Delhi-metallo-beta-lactamases (NDM-1), hampered the
capability of all antibiotics of beta lactam group to treat
infections caused by microorganisms carrying such resis-
tances. The possible reason for evolving trends of new
markers is mutations [1], which may cause delaying in the
discovery of new antibiotics for treatments and hence
became a great public threat [2]. The overuse of antibi-
otics is one of the reasons to cause resistance, due to
increase selective pressure in a specific population of
bacteria allowing the resistant bacteria to bloom and
the susceptible bacteria to pass away.
Enzymes are evolving over a period of time by muta-
tions in response to environmental pressure for increased
stability and fitness leading to its functional changes. The
activity of an enzyme and its future generations success in
response to change conditions due to environmental
stress and its improved physiological utility for constant
perseverance is determined by these evolutionary drivers.
Recent reports on antibiotic resistance has made a clear
understanding of evolving status of β-lactamase enzymes,
which are key player for antibiotic resistance [3].
In Enterobacteriaceae and other Gram-negative
bacteria including Pseudomonas and Acinetobacter
species, production of carbapenemases has become a
noteworthy mechanism for broad-spectrum β-lactam
resistance [4]. Carbapenemases may be defined as specific
beta-lactamases, which hydrolyze carbapenem group of
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antibiotics. These are involved in acquired resistance and
belong to Ambler molecular classes A, B and D [4].
Intestinal carriage of carbapenemase-producing organ-
isms (CPOs) is an important source of its transmission [5].
However, detection of carbapenemase producing Gram-
negative bacteria has become a major concern for the
hospital settings to control infections. Use of multiplex
PCR analyses and DNA microarray have been reported as
rapid detection systems. Most prevalent carbapenemases
detected by these systems are KPC and OXA serine
carbapenemases [6].
A number of new variants of class A carbapenemases
(e.g., KPC and GES enzymes), class B metallo-beta-
lactamases (e.g., IMP, VIM and NDM metallo-beta-
lactamases), and class D carbapenemases (e.g., OXA-23)
are emerging over time scale. Moreover, over-expression
of class C beta-lactamases, such as CMY-10 and PDC type
beta-lactamases, which are weak carbapenemases, can also
lead to carbapenem resistance, especially in combination
with other resistance mechanisms [7].
Metallo-beta-Lactamases (MBLs) are class B β-lactamases
that hydrolyze almost all clinically-available β-lactam
antibiotics and feature the distinctive αβ/βα sandwich
fold of the metallo-hydrolase/oxidoreductase superfamily.
MBLs possess a shallow active-site groove with one or
two divalent zinc ions, bordered by flexible loops [8]. In
NDM-1 this flexible hairpin loop moves over the zinc ion
for hydrolysis and is later removed after the catalysis [9].
The 3D structure of NDM-1 with active site and Zinc
molecules is shown in Fig. 1. MBLs are classified into
three subclasses (B1, B2 and B3), according to sequence
identity and zinc ion dependence, of which the B1 sub-
class included most clinically significant enzymes. Not
many inhibitors have been successfully designed due to
the nature of zinc ligands, catalytic mechanisms and the
differences among the active site architecture [8]. The
evolution of varied and detrimental range of β-lactamases
has lost the effectiveness of β-Lactamase inhibitors (BLIs)
which could play an important role in combating β-lactam
resistance in Gram-negative bacteria [10]. A triple
combination of meropenem/piperacillin/tazobactam
β-lactams, has been proved as one of the strategies to
kill Methicillin-resistant Staphylococcus aureus (MRSA) in
vitro as well as in a mouse model through a novel
synergistic mechanism of action [10].
A bacterium carrying several antibiotic-resistant genes
is called multi-resistant bacteria or informally, a “super
bacteria” or “super bug”; infections caused by them are
Fig. 1 3D structure of NDM-1 protein backbone shown with helices and strands, the two zinc ions at the active sites are shown as blue spheres
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difficult to treat [11]. Most probably, a very rare “genetic
fusion” is thought to occur between two previously
known antibiotic-resistant genes that evolved to a new
mutant called NDM-1.The product of the blaNDM-1 gene
is NDM, an enzyme hydrolysing broad range of antibi-
otics, including the carbapenems, which are considered
as last resort of antibiotics. In the last few years, 17 new
variants of NDM-1 have been evolved by changing one
or two residues at different positions [12–15]. The emer-
gence of bacteria carrying such genes represent a big
challenge for physicians to treat infected patients.
Mechanism of resistance
The expression of β-lactamases, efflux pumps and alter-
ation of porins and penicillin binding proteins (PBPs) are
the common mechanism for carbapenem resistance in
member of Enterobacteriaceae. Combinations of these
mechanisms can cause high levels of resistance to carba-
penems in certain bacterial species, such as K. pneumo-
niae, Pseudomonas aeruginosa and A. baumannii. In P.
aeruginosa carbapenem resistance is contributed also by
the loss of OprD porin leading to decrease in outer mem-
brane permeability, increase in cytoplasmic membrane
active efflux pump system, up regulation and alteration in
carbapenem hydrolyzing enzymes and penicillin binding
proteins [16]. Acquisition of metallo-beta lactamases
(MBL), which hydrolyze the carbapenems and all beta
lactams except the monobactams, is one of the emerging
mechanism of carbapenem resistance [17]. Multi-drug-
resistant Pseudomonas aeruginosa (MDRPA) infection risk
factors include immunocompromised states, prolonged
hospitalization and antimicrobial therapy [18]. NDM-1
producing P. aeruginosa isolates were detected for the
first time in Serbia [19]. In all four P. aeruginosa iso-
lates detected, blaNDM-1 genes were present on 50 kb
plasmid (Gene Bank accession numbers JX680682,
JX680683, JX680684 and JX680685) [20].The co-expression
of blaNDM-1 and MexAB-OprM efflux pump occurred into
a P. aeruginosa strain upon single dose of meropenem
therapy, thus suggesting that both mechanisms contribute
to carbapenem resistance, although the efflux system
played the major role [21]. One more example of com-
binatorial effects in A. baumannii harbouring blaNDM is
the expression of multiple efflux systems and altered
membrane permeability [22].
A distinction exists between resistance to carbapenems
in Gram-positive cocci and Gram-negative rods. In
Gram-positive cocci, carbapenem resistance is typically
the result of substitutions in amino acid sequences of
PBPs or acquisition/production of a new carbapenem-
resistant PBP. Expression of beta-lactamases and ef-
flux pumps, as well as porin loss and alterations in PBP,
are all associated with carbapenem resistance in Gram-
negative rods [23]. For example, a clinical strain HPC299
Acinetobacter bereziniae, harbouring blaNDM-1, uses
multidrug efflux pumps as its adaptation strategy for
survival under different environmental conditions
[24]. Carbapenem resistance mechanisms not related
to carbapenemase production include increase in ef-
flux pump activity [25] and modifications of outer
membrane porin profiles, which regulate access of
carbapenems to the cell wall [26].
Multi-drug resistance by ndm-1 producing bacteria
Background of NDM-1 producers
There are hundreds of commensal strains of E. coli bacteria,
which are not associated with any infectious diseases. How-
ever, emergence of a new mutant strain known as NDM-1
producing E. coli has thrown light on the fact that the de-
velopment of antibiotic resistance among microorganisms
can transform commensals into pathogens. Many NDM-1
variants evolved in Enterobacteriaceae, Vibrionaceae and
other non-fermenters by single and double amino acid
residue substitutions at different positions [27], for e.g.,
NDM-1 (major variant), NDM-2, NDM-3, NDM-4and
NDM-5 (minor variants), reported worldwide [12, 28, 29].
New Delhi metallo-beta lactamase (NDM) produced by
bacterial isolates from the Indian subcontinent are
the latest carbapenemases, which hydrolyze all beta
lactam antibiotics (except aztreonam), including the broad
spectrum antibiotic “carbapenems”, thereby causing
havoc in hospitals and community [30]. The gene en-
coding NDM-1 is often carried by plasmids and hence
easily moves to other microorganisms via horizontal gene
transfer, thereby increasing the probability of emergence of
drug resistant strains of pathogenic microorganisms [31].
Major healthcare risk of NDM producers
NDM-1 strains are particularly hazardous because:
(i) most plasmids detected in these bacteria are transfer-
able and capable of wide rearrangement, suggesting a
widespread horizontal transmission and flexibility among
bacterial populations; (ii) there is lack of a routine standard-
ized phenotypic test for metallo-beta-lactamase (MBL)
detection; (iii) there is consequent probable high prevalence
of unrecognized asymptomatic carriers; (iv) there is a lack
of available effective antibiotics for the treatment of multi-
drug resistant NDM-1 expressing bacteria [31].
NDM-1 producing E. coli infects the host by commonly
invading sites like, urinary tract, blood, lungs, and wounds,
leading to urinary tract infections, septicaemia, pulmonary
infections, diarrhoea, peritonitis, device-associated in-
fections and soft tissue infections [12]. These antibiotic
resistant bacteria express type IV secretion system as
their virulence factor, which allows them to introduce
bacterial proteins and enzymes inside the host cell,
thereby controlling the host cell metabolism [32]. Mode
of transmission of NDM-1 producing strain could either
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be through cross-contamination during food preparation
or via body fluids and may occur in the community or in
the hospital setting [33].
Worldwide distribution of NDM variants across the globe
Asian continent serves as the major reservoir of NDM
producers, with around 58.15% abundance of NDM-1
variant distributed mostly in China and India. Additional
file 1: Table S1 shows detailed prevalence of NDM-1 and
its variants in different countries worldwide. Europe shows
around 16.8% of the total producers, with the maximum
spread of NDM-1 variant in Bulgaria, Romania, Poland,
France, Italy, Turkey, Germany, Greece, Serbia, London,
Ukraine, Croatia, Azerbaijan and Ireland. NDM-4 is also
reported to be distributed in European subcontinent in
Italy, while NDM-5 and NDM-7 are prevalent in Denmark
and France (Additional file 1: Table S1). American contin-
ent shows around 10.8% abundance of the total NDM-1
producers as reported globally, of which subcontinent
Brazil serves as the major reservoir while Colorado,
Mexico city, California, Georgia, Illinois, Paraguay, Pennsyl-
vania, Florida, Argentina, Jamaica, Uruguay and Ecuador are
considered as minor pool (Additional file 1: Table S1). Africa
carries around 10.8% pool of the total NDM-1 producers
scattered globally. African subcontinent, Algeria showed
major distribution, whereas Greater Johannesburg Area,
KwaZulu-Natal, Libya, Madagascar, Egypt and Tunisia dem-
onstrated low prevalence of these NDM-1 producers.
NDM-5 is also reported to be distributed in Algeria (Add-
itional file 1: Table S1). Australia serves as the 1.6% reservoir
of the total NDM-1 producers distributed in Brisbane, Perth
and New Zealand. Highest distribution of these NDM vari-
ants is detected in K. pneumoniae and E. coli species (Add-
itional file 1: Table S1).
NDM-1 producers were found resistant to imipenem,
meropenem, ertapenem, gentamicin, amikacin, tobra-
mycin, and ciprofloxacin, whereas, isolates were found
susceptible to colistin (MICs ≤4 mg/L) and to tigecyc-
line (MICs ≤1 mg/L) [34]. Non-clonal Indian isolates
from Chennai had blaNDM-1 exclusively on plasmids of
size ranging from 50 to 350 kb, whereas another clone
of K. pneumoniae isolated in Haryana was found to
have plasmid of predominately either 118 kb or 50 kb,
suggesting wide environmental spread of blaNDM-1
[34]. Plasmid profiling showed that a plasmid of size
50 kb carries blaNDM-1in Enterobacteriaceae, which
were found resistant to almost all antimicrobials ex-
cept tigecycline and colistin [34].
In Europe, dissemination of NDM-1 has been observed
in A. baumannii isolates assigned to international clonal
lineage I and to the emerging genotypes ST25 and ST85
[35, 36]. The blaNDM-1 gene was inserted within a Tn125-
like transposon which was either chromosomally-located
[35] or plasmid-located [35, 36] (Fig. 2).
NDM-producing resistant E. coli strains were also found
in animal sources [37]. Acinetobacter lwoffii carrying
blaNDM-1 gene on plasmid were isolated from chicken rec-
tal swab [38]. The blaNDM gene detection in dairy cattle is
a matter of concern because it may lead to spread through
food chain. Sequence analysis revealed a gene showing
100% homology with E. coli (JQ348841.1) blaNDM-5 gene
and 99% homology with E. coli (JQ348841.1) blaNDM-4 in
Pseudomonas aeruginosa (HF546976.1), K. pneumoniae
(KC178689.1), Raoultella ornithinolytica (JX680686.1), A.
baumannii (KC404829.1, KC347597.1). Apart from this,
NDM-1 producing Enterobacter cloacae (EC15) and K.
pneumoniae (KP12) strains were isolated from two pa-
tients with diabetic foot ulcers in 2010 from northern part
of India [39].
The origin of NDM-1 started in the year 2008 when
the first case of a NDM-1 episode was reported in a
Swedish patient previously hospitalized in New Delhi,
suffering from a multidrug-resistant K. pneumoniae, urin-
ary tract infection [40]. Based on the number of victims
affected with NDM-1 strains in various parts of the globe, it
has been estimated that the Indian subcontinent is the
main reservoir of NDM-1 producers [39], next down the
line is United Kingdom. On the other hand, Belgium,
China, Japan, France, Austria, Germany, Norway, Hong
Kong, Sweden, Netherland, Australia and Canada also serve
as the secondary reservoirs of blaNDM genes [39] as shown
in Additional file 1: Table S1. An average of 1000–1600
patients are admitted daily to the hospitals worldwide as a
result of infections due to drug resistant bacteria [41]. It is
difficult to predict the rate of spread of the gene encoding
NDM- 1, although exchange of the blaNDM-1 gene among
unrelated bacterial isolates have been identified already in
Enterobacteriaceae and A. baumannii [34]. An increase in
population exchange at global level and enhanced medical
tourism could play a significant role in spreading uncon-
trolled NDM-1 related resistance worldwide.
Genetic and Biochemical analysis of NDM variants
The blaNDM-1 gene which encodes for the New Delhi
metallo-β-lactamase 1 (NDM-1) is commonly found among
members of Enterobacteriaceae and Pseudomonas species
[34, 42]. The above bacteria are highly resistant to all antibi-
otics including carbapenems and aminoglycosides because
of co-existence of rmtF methylase gene in most of the iso-
lates [43], but susceptible to tigecycline and colistin [34].
However, blaNDM-9 producing colistin resistant E. coli strain
was recently discovered in a chicken meat sample in
Guangzhou, China [44]. 16S rRNA methyl transferases
responsible for high resistance to antibiotics were reported
in blaNDM-1 positive Pseudomonas aeruginosa isolates
in co-association with rmtC and rmtF genes on the
chromosome [45]. IncR plasmid carrying blaNDM-1 was
also reported in Citrobacter koseri acting as a reservoir
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for multidrug resistance [46]. bla NDM-1 was associated
with different plasmid scaffolds (IncFII, IncL/M, IncN,
IncR, IncHIB-M/FIB-M), IncF type being the prevalent
one. Genetic structures surrounding bla NDM-1 showed
its association with at least a remnant of ISAba125 at its 5′-
end [47]. Tn125 composite transposon in A. baumannii
has been demonstrated to be responsible for blaNDM-1 gene
dissemination within Acinetobacter species and Entero-
bacteriaceae [48]. bleMBL gene, which confers resistance
to anti-tumor glycopeptide molecule bleomycin, is found
downstream of blaNDM-1 gene [49] (Fig. 2). There has
been an exponential increase in resistance among Gram-
negative bacteria compared with Gram-positive bacteria
[50, 51], while not many new active antibiotics are devel-
oped against Gram-negative bacteria [52–54]. Increase in
its resistance is mainly due to the presence of mobile
elements into conjugative plasmids, which can readily
spread through bacterial populations.
The isolates obtained from UK had a more diverse
range of plasmid sizes ranging from 80 kb to greater
than 500 kb [34]. For example, a RB151 strain was reported
to harbour 108 kb plasmid carrying NDM-1 gene on 4.8
Mbp chromosome [55]. E. coli Y5 isolate was found to have
blaNDM-1 on chromosome as well [56].The blaNDM-1 was
also carried by more than one plasmid in some isolates.
Most of the plasmids carrying blaNDM-1 shows transmissi-
bility and plasticity enabling them to diversify and spread
among bacterial populations with an alarming potential;
many of them were of incompatibility A/C types [34],
which is not commonly associated group among multidrug-
resistant phenotypes. The emergence of new variants of
NDM-1 are taking place in India due to widespread use of
antibiotics leading to huge selection pressure. Only few anti-
biotics against Gram-negative bacteria are available and
none of them is active against producers of NDM-1 [57].
Large conjugative plasmids are seen to harbour blaNDM-1
gene along with determinants of antibiotic resistance [58].
In the United States, K. pneumoniae is the most common
CRE (carbapenem-resistant Enterobacteriaceae) species, re-
sistant to nearly all available antibiotics encountered, typic-
ally as a hospital-acquired infection with high mortality and
morbidity rate [59, 60]. ATCC BAA-2146 (Kpn2146) a
Fig. 2 A schematic representation of blaNDM-1 gene carrying Tn125 transposon, showing the mutations at various nucleotide positions leading to
the occurrence of NDM variants. Each unique colour of NDM variant in lower panel showing mutant residues at different position and the same
is reflected in gene with the same colour at different position and nucleotide (s)
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strain of K. pneumoniae was the first reported U.S iso-
late encoding NDM-1 along with additional antibiotic
resistance determinants on plasmid of size 140.8 kb.
At least one zinc atom is present on the active site of all
metallo-carbapenemases, which facilitates bicyclic β-lactam
ring hydrolysis [61]. Metallo-carbapenemases have the
ability to hydrolyze commercially available carbapenem
resistant β-lactamase inhibitors but show sensitivity to
metal ion chelators. Along with carbapenems they can
also hydrolyze penicillins and cephalosporins, while the
ability to hydrolyze aztreonam is lacking. Hydrolysis
occurs when zinc ions on active site interacts with β-
lactams giving distinctive inhibition trait by EDTA.
It has been reported that the blaNDM is carried by various
types of plasmids such as IncA/C, IncF, IncNIncL/M or
untypable/IncR, and is rarely found to be chromosomally
integrated [62]. Plasmid characterization demonstrated that
different mechanism leads to acquisition of NDM gene
even if it is located on very closely related plasmids [63].
The sequencing of few plasmids reveals blaNDM association
with insertion sequences and transposons, which regulate
its horizontal gene transfer and aadB, dfrA12, blaOXA-30
and aacA4 additional resistance markers [64]. Tn3000
transposon has been reported to be responsible for blaNDM-1
dissemination among enterobactericeae [65]. A non-active
site residue Trp 93 is found to play role in maintaining
the structural integrity of NDM-1, although not being
directly involved in recognition and catalysis [66]. Recently,
a new plasmid type IncX3 is reported to be responsible for
making the spread of NDM gene more effective [67], for
example in China IncX3 and InA/C plasmids were reported
to be responsible for spread of blaNDM genes [68].
Recent studies demonstrated the coexistence of NDM-1
gene along with other resistant genes, such as IMP-1 in
Acinetobacter species [69], co-expression of NDM-1 and
OXA-232 in an E. coli isolate was reported from Germany
[70], co-production of NDM-5 and MCR-1 in ST648 and
ST156 E.coli isolates from fowl in China [71]. Coexistence
of blaNDM-1 and blaOXA-48 carrying plasmids was reported
in an isolate of K. pneumoniae from China [72]. Similarly,
coexistence of blaNDM-1 and blaOXA-23 was reported in A.
baumannii from Nepal [73]. K. pneumoniae of type 11
was reported in Greek to be coproducing two metallo
beta-lactamses markers, NDM-1 and VIM-1 together [74].
A report on E. coli isolate obtained from a patient in
Thailand and another report from China, showed the
presence of colistin resistant mcr-1 gene along with beta
lactamases genes such as NDM-1 [75–77]. In E. coli
ST471 isolated from Turkey, NDM-1 was found present
along with CTX-M-9, TEM, SHV and rmtC [78]. Another
coexistence of blaSHV-12 along with blaNDM-13 on a self-
transferable plasmid of about 54 kb size isolated from E.
coli in China was reported [79]. Coproduction of NDM-5
along with mcr-1 in China, NDM-7 along with OXA-48
in Spain and NDM-9 along with MCR-1 in Taiwan was
reported recently [80–82]. Also, the presence of both
NDM-9 and MCR-1 was reported in Cronobacter sakaza-
kii and E. coli [83].
To date, a number of variants of New Delhi metallo-
β-lactamase-1(NDM-1) have been reported. Of these
variants, NDM-2 had a substitution of Cysteine to
Glycine at position 82, and amino acid being substituted
by alanine at position 28 in place of proline, in A. bau-
mannii [84] (Table 1). However, 16S RNA methylase and
extended-spectrum- β-lactamases were not detected.
Moreover, strains carrying blaNDM-2 lacked detectable
plasmids and the blaNDM-2 was not seen to be trans-
ferred by conjugation [84].
Another variant NDM-3 with an amino acid substitution
of Aspartate to Asparagine at position 95 was observed in
E. coli [85] (Table 1). NDM-3 showed similar enzyme activ-
ities against β-lactams like those of NDM-1, although
slightly lower Kcat/Km ratios for all the β-lactams tested
except for doripenem was seen, which is caused by the
lower Kcat values of NDM-3 being 19.0 to 47.5% as
Table 1 Genetic variations among the NDM-1 and its variants
and its first source of spread
NDM-1
variants
Amino acid(s) substitution Source organism(s)
NDM-2 Proline 28 to Alanine Acinetobacter baumannii
NDM-3 Aspartate 95 to Asparagine Escherichia coli
NDM-4 Methionine 154 to Leucine Escherichia coli
NDM-5 Valine 88 to Leucine
Methionine 154 to Leucine
Escherichia coli
NDM-6 Alanine 233 to Valine Escherichia coli
NDM-7 Aspartate 130 to Asparagine
Methionine 154 to Leucine
Escherichia coli
NDM-8 Aspartate 130 to Glycine
Methionine 154 to Leucine
Escherichia coli
NDM-9 Glutamic Acid 152 to Lysine Klebsiella pneumoniae
NDM-10 Arginine 32 to Serine,
Glycine 36 toAspartic acid,
Glycine 69 to serine,
Alanine 74 to threonine,
Glycine 200 to Arginine
Klebsiella pneumoniae
NDM-11 NA Escherichia coli
NDM-12 Glycine 222 to Aspartic acid
and Methionine 154 to Leucine
Escherichia coli
NDM-13 Aspartic acid 95 to Asparagine
and Methionine 154 to Leucine
Escherichia coli
NDM-14 Aspartic acid 130 to Glycine Acinetobacter lwoffii
NDM-15 Alanine 233 to valine
Methionine 154 to Leucine
Escherichia coli
NDM-16 Arginine 264 to Histidine Klebsiella pneumoniae
NDM-17 Valine 88 to Leucine, Methionine
154 to Leucine and Glutamic acid
170 to Lysine
Escherichia coli
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compared to NDM-1 [86]. In fact, the decreased Kcat values
and the decrease in hydrolysis rate of all tested β-lactams
except for doripenem is due to subsitution of Asn from
Asp at position 95. Residue 95 is found to be in α1, located
on the surface of the protein [86]. The crystal structure
study of NDM-1 revealed that the NDM-1 active site is lo-
cated at the bottom of a shallow groove being enclosed by
two important loops named L3 and L10. However, α1 95th
residue was not located in these loops and indirectly may
affect the interaction of the substrate with the active site
[86]. Among 9 NDM variants, substitutions of amino
acids were identified at 7 different positions (28, 88, 95,
130, 152, 154, and 233), but which position(s) plays a
critical role in the enzymatic activities, remained unclear.
For blaNDM-3 the genetic context tnpA-blaNDM-3-bleMBL-
trpF-dsbC-tnpA-sulI-qacEdeltaI-aadA2-dfrA1, was present
on approximately 250-kb plasmid. The blaNDM-3 and
blaNDM-1 gene expression in E. coli DH5α conferred reduced
susceptibility and resistance to all cephalosporins, moxalac-
tam, and carbapenems. E. coli expressing NDM-3 showed 2-
fold higher MIC of cefpirome than the one expressing
NDM-1 in contrast to those of 2-fold lower MIC of cefe-
pime, cefoselis, cefotaxime, cefoxitin, imipenem, merope-
nem, and penicillin G for NDM-3 than NDM-1.
Recombinant NDM-3 and NDM-1 hydrolyzed all tested β-
lactams except for aztreonam [86].
NDM-4 variant showed substitution of amino acid from
154th Methionine to Leucine in E. coli [87] (Table 1).
NDM-4-producing E. coli isolate from a North Indian
hospital sewage was recently reported by Khan and Parvez
[15]. Gene expression of blaNDM-1 and blaNDM-4 in E. coli
TOP10 conferred lower susceptibility or resistance to all
β-lactams except aztreonam. However, the MICs of imipe-
nem and ertapenemwere found to be higher for E. coli
expressing NDM-4 than the one expressing NDM-1, sug-
gesting the role of Leu154 residue in the high carbapene-
mase activity [87]. NDM-4 β-lactamase hydrolyzed all
tested β-lactams except for aztreonam, just similar to
other MBLs. Kinetic data showed higher level of hydroly-
sis of imipenem by NDM-4 than by NDM-1. Similarly,
catalytic activity of NDM-4 for meropenem was slightly
higher than that of NDM-1. NDM-4 showed higher cata-
lytic efficiencies for cefalotin, ceftazidime, and cefotaxime,
as cefepime was less hydrolyzed by NDM-4. Higher Kcat
values for NDM-4 than NDM-1 for cefalotin and cefotax-
ime was also observed. Km values of 72 and 181 μM for
NDM-4 and NDM-1 was observed, respectively. NDM-4
showed lower affinity for ceftazidime than NDM-1 [87].
blaNDM-4 was found on IncF type plasmid in one of the
earlier studies [88]. A remnant of insertion sequence
ISAba125 on upstream of the blaNDM-4was found previ-
ously by PCR mapping during study of genetic structures
surrounding the blaNDM-4 gene [89]. The bleMBL, a bleo-
mycin resistant gene, was identified downstream of the
blaNDM-4, similar genetic environment has been ob-
served for most of the analyzed NDM-1 positive en-
terobacterial isolates [88]. PCR-based replicon typing
showed that this blaNDM-4 positive plasmid belongs to the
IncFIA incompatibility group. In keeping with this,
blaNDM-5 was also found associated with IncFIA [28, 87].
The substitution of Valine by Leucine at position 88
and Methionine by Leucine at position 154 was found in
NDM-5, which was first detected in E.coli [28] (Table 1).
NDM-5 shows greater hydrolytic activity than NDM-1
toward carbapenems, cefotaxime, cephalotin and ceftazi-
dime [85]. NDM-5 carrying plasmid of size >100 kb reduced
susceptibilities of E. coli transformants to carbapenems and
cephalosporins [28]. Other detected resistance determinants
in NDM-5 producing E. coli included dfrA17 and aadA5
genes, which were found to be located within a class I inte-
gron structure, and the 16S rRNA methylase gene, rmtB,
which was thought to account for aminoglycoside high-level
resistance. The effect of NDM-5 on susceptibility of E. coli
to carbapenems and expanded-spectrum cephalosporins ap-
peared to be greater than that of NDM-1. Sequence analysis
of 5′-flanking region of blaNDM-5 allele revealed presence of
partial ISAba125, likely to be derived from A. baumannii,
which generated a hybrid (−35/−10) promoter as described
earlier by Poirel et al. in an NDM-1-producing E. coli
isolate [90]. NDM-6 showed substitution of Alanine to
Valine at 233 position, again first time detected in E.
coli [12] (Table 1).
Substitutions of Aspartate to Asparagine at position
130 and Methionine to Leucine at position 154were
found in NDM-7, identified in E. coli ST599 [91] (Table 1).
TOP10 cells carrying plasmid harbouring blaNDM-7 in E.coli
conferred higher resistance to carbapenems than a plasmid
carrying blaNDM-1 [91]. A recent report demonstrated the
role of Leu154 in enhancing carbapenem MICs in NDM-7
producing E. coli strain [91]. The blaNDM-7 gene was found
to be located on a self-transferable IncX3 plasmid of 60 kb.
NDM-8 variant having substitutions at positions 130th
(Aspartic acid to Glycine) and 154th (Methionine to
Leucine) resulted in enzymatic activities against β-lactams
similar to those shown by NDM-1 [92]. NDM-9 differing
by a single amino acid substitution (E152K) from NDM-1
was recently identified in K. pneumoniae ST107 strain
from China [93].
NDM-10 was first identified in K. pneumoniae isolated
from Maharashtra, India and was found to have mul-
tiple substitutions at Arginine 32 to Serine, Glycine 36
to Aspartic acid, Glycine 69 to Serine, Alanine 74 to
Threonine and Glycine 200 to Arginine [94].
NDM-11 was reported in E. coli KnPEc14 strain (Gene
Bank KP265939.1).
NDM-12 has two amino acid substitutions at 154th
(Methionine to Leucine) and 222th (Glycine to Aspartic
acid). It was first identified on plasmid size 160 kb in E. coli
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[95] (Table 1). NDM-12 enzymatic activities were
similar to those of NDM-1 against β-lactams, although
kcat/Km ratios for all β-lactams were tested except
doripenem.
NDM-13, a novel New Delhi Metallo-β-lactamase was
identified in Nepal from the urine sample of patient show-
ing a carbapenem-resistant E. coli infection [96]. It showed
substitutions of Asparagine in place of Aspartic acid at pos-
ition 95 and Leucine in place of Methionine at position 154
(Table 1) and similar enzymatic activity against β-lactams,
but higher Kcat/Km ratios for cefotaxime compared with
NDM-1. The blaNDM-13 gene was located into the chromo-
some within the genetic environment of tnpA-IS30-
blaNDM-13-bleMBL-trpF-dsbC-cutA-groES-groL. Recently,
complete sequence of pNDM13-DC33 plasmid harbouring
blaNDM-13 isolated from E. coli isolate ST5138 in China, was
reported, consisting of a backbone of 33 kb size and
encoding an antimicrobial resistance region of 21 kb; tra, trb
and pil transfer functions; repB plasmid replication gene and
stability partitioning. pNDM13-DC33 plasmid harbouring
blaNDM-13 gene showed high similarity with pNDM-HN380
IncX3 plasmid harbouring blaNDM-1 gene [79].
NDM-14 was first identified in clinical isolate of
Acinetobacter lwoffii with substitution of Aspartic acidat
130th position to Glycine [97] (Table 1). NDM-14 showed
higher enzymatic activities than NDM-1 towards carba-
penem. NDM-14 have higher affinity for meropenem
and imipenem than NDM-1, as indicated by the kinetic
data [97].
NDM-15 was reported in an E. coli strain (Gene Bank
KP735848.1). It showed substitution of Alanine to valine at
233th position and Methionine to Leucine at 154th position.
NDM-16 variant showed substitution at 264th position
of Arginine to Histidine [98].
NDM-17 was reported in E.coli strain from a chicken
in China. It showed amino acid subsitution of valine 88
to leucine, methionine 154 to leucine and glutamic acid
170 to lysine [99]. Schematic representation of muta-
tions on various nucleotides leading to formation of new
NDM variant is shown in Fig. 2. Phylogenetic analysis
among the protein sequence of NDM variants are repre-
sented as cladogram in Fig. 3.
Carbapenem hydrolysing activity was gradually reduced
from NDM-7 to NDM-5, NDM-6 and NDM-1. All
Fig. 3 The phylogenetic relationship between protein sequences of NDM variants is shown. The tree construct has been generated using
Phylogeny.fr, which used the maximum likelihood method to generate phylogenetic tree [107, 108]
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isolates positive for variants of blaNDM-1 showed resist-
ance to aminoglycosides with MIC greater than 256 mg/L
and MIC range of 2–512 mg/L for different lactams, lac-
tams/lactamase inhibitor combinations [100]. Moreover,
these variants showed susceptibility to tigecycline and co-
listin except for KNKp6a isolate, which showed MIC of
1.5 mg/L to tigecycline [100].
NDM variants were found associated with all other
groups of antibiotic resistance enzymes encoding genes
i.e. ESBL, carbapenemase, AmpC and rRNAmethylase.
In blaNDM and its variants, due to genetic co-existence
of other antibiotic resistant markers, there is limited op-
tions left to treat infections [101].
Recently, an NDM-1 producing Cedecea lapagei isolated
from a neonate admitted to the paediatric ICU of a north
India hospital was reported from our lab [102]. Also, a re-
cent study demonstrated that 11 out of 55 patients with
carbapenem-resistant Enterobacteriaceae nosocomial infec-
tions in China showed NDM variants as carbapenemase
genes [103]. Recently, metabolite aspergillomarasmine A
(AMA) which is found in fungi and its natural LLL isomer
were identified to be effective inactivators of NDM-1 en-
zyme both in vivo and in vitro [104]. Also, the combination
of levofloxacin and tigecyclinewas recently reported to
successfully treat nosocomial pneumonia caused by
NDM-1 producing Raoultella planticola [105].
Conclusion
The continual evolution of resistant markers due to the
selection pressure and their spread among the bacteria
through horizontal gene transfer is one of the alarming
threats to the health worker in the hospital settings in
order to control infections. NDM-1 and its variants
producing bacteria was one of the challenges, which has
became even more urgent since the detection of mcr-1
gene in Chinaand the spread of resistance against colis-
tin has ended all hopes to control infections [77]. Now
this is a time to think prudently the ways to check infec-
tions from hospital settings and to coordinate globally
for surveillance of such resistant markers producing
bacteria. Proper infection control guidelines need to be
implemented worldwide. Surveillance should also be
carried out to identify undetected asymptomatic car-
riers of carbapenem-resistant bacteria. To discover new
drug molecules which could fight with multi-resistant
bacteria, Infectious Disease Society of America has
launched a “bad bugs need drugs” campaign to promote
development of new antibiotics by 2020 [106].
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